NYSE: $ABBV A Breakthrough in Atopic Dermatitis Treatment For millions of people living with moderate-to-severe atopic dermatitis (eczema), the search for more effective and convenient treatment options is ongoing. Recently, AbbVie provided an encouraging update regarding their clinical development program, announcing positive top-line results from the Phase 2 APEX study for their investigational therapy, zumilokibart.…